Casey Laycock: Spotlight on Community Champion – Jon Schneider of Spire
Casey Laycock, Campaign Development Manager at Blood Cancer United, shared a post on LinkedIn:
“Spotlight on Community Champion: Jon Schneider of Spire
I’m thrilled to celebrate Jon Schneider, whose dedication to the St. Louis community continues to make a real and lasting impact. Whether he’s rolling up his sleeves as a regular platelet donor for pediatric blood cancer patients or lending his voice and leadership to local causes, Jon leads with heart, humility, and purpose.
This year, we’re especially grateful to have Jon serve as a 2026 Light The Night – St. Louis Executive Committee Member, helping to lead the way for Blood Cancer United. His commitment to giving back-and his hands-on support for families facing blood cancer-perfectly reflects the spirit of Light The Night and our mission.
Please join me in thanking Jon for shining so brightly for our community. We’re incredibly fortunate to have leaders like him lighting the path forward.
If you’re interested in becoming an executive champion for change, you can connect with me directly at [email protected]”
Stay updated with Hemostasis Today.
-
Mar 26, 2026, 17:16Rebecca Mellema: Journal Club Spotlight on Layilin and Platelet Hyperactivation in Inflammatory Bowel Disease
-
Mar 26, 2026, 17:15Shalom Zwiebel: Clinical Practice Evaluating PRP Systems and Supply Partners
-
Mar 26, 2026, 17:14Olivia C.: Pfizer’s mRNA BNT162b2 Vaccine Does Not Induce High Levels of Inflammation
-
Mar 26, 2026, 17:03Tilden Sokoloff: PRP Injections Enhance Sexual Function in Premenopausal Women
-
Mar 26, 2026, 17:02Mahesan Subramaniam: Japan Brings Mitochondrial Therapy to the Frontline of Cardiology
-
Mar 26, 2026, 17:01Kanishk Kumar: Discovering The Newest Advances in Hypercholesterolemia Research
-
Mar 26, 2026, 17:00Ifeanyichukwu Ifechidere: Breaking the INR Myth in Liver Disease
-
Mar 26, 2026, 16:57Georgiana Toma: Why Nutrition is a Hematologist’s Secret Weapon
-
Mar 26, 2026, 16:56Anu Anna Babu: Which DOAC is Safer for Patients With Acute Venous Thromboembolism?